# HSEF v5.3 review: Berberine and Glycemic Control

> Sources: 63 primary reports; claims: 68; verified: 68; unverified: 0. Verification is bounded attribution. Access: 4 partial-body and 59 bounded abstract/status examinations. Literature cutoff: 2026-10-13; source examination UTC date: 2026-10-13. No complete-paper audit or blinded calibration claimed.
> **Adversarial review:** Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 7 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: **Approved as revised.**

## AT A GLANCE

**Defined berberine can improve short-term T2D glycemic control; modern GLP-1 equivalence, broad weight-loss claims and exact glutathione/NMN stack benefits require separate evidence.**

| Level | Confidence | Causal role | Momentum | Stability | Divergence |
|---|---|---|---|---|---|
| Δ — First field-valid causal perturbation crossed | Moderate | reinforcing / stabilizing factor | Mechanistic only | Stable | Contested |

**Deciding experiment:** Run a multisite, baseline-stratified, double-blind trial of chemically verified ordinary oral berberine versus matching placebo added to unchanged standard T2D care, with prespecified twelve-month glycemic durability and adverse-event outcomes. Include strata for baseline HbA1c, disease duration and fixed co-medication; avoid routine antibiotic pretreatment or randomize that factor separately if mechanistically essential. Add prespecified pathway measurements and an orthogonal mediator-dissociation component rather than declaring correlated microbiome changes necessary. Evaluate GLP-1 equivalence and the exact triple stack in separate properly controlled trials.

**Belief versus evidence:** The preregistered primary-subclaim rule returns Δ from SC2: defined oral berberine has a positive controlled treatment effect on twelve-week T2D glycemic control. The claim is deliberately narrower than weight loss, GLP-1 equivalence, complication prevention or rejuvenation stacks. Sixty-three original reports include clinical efficacy, exposure and interaction studies, relevant model experiments and companion ingredients; they are not sixty-three isolated T2D efficacy trials. Weakest-link returns Α because the separate equivalence and exact-stack companions lack direct evidence; primary-subclaim and scope-matched return Δ. Repeated trials increase confidence but do not automatically become independently failing causal lines or identify a unique mediator.

**Best-supported rival:** Metabolic engagement is multiple and does not establish class equivalence (Γ) — the highest-ranked model other than the nominal, which itself holds rank 1. KCNH6-dependent secretion, SIRT3 and gut-absorption perturbations and a nontransferable microbiome result (PMID34556670,30117113,33994854) show several routes that could each carry part of the effect, and the large diabetes-free obesity trial shows lipid markers moving while adiposity and glycemia do not (PMID41543854). Nothing in that set identifies a uniquely necessary human mediator or demonstrates GLP-1 equivalence, and it does not displace PREMOTE's randomized incremental ordinary-berberine contrast (PMID33024120), which is why the nominal still ranks first.

## COMPETING MECHANISTIC MODELS

**Rank 1: Defined berberine has a glycemic treatment effect (Δ).** Oral berberine itself contributes to glycemic control in adults with T2D under tested conditions. Concealed placebo-controlled PREMOTE isolates ordinary berberine from probiotics and demonstrates incremental HbA1c benefit (PMID33024120); the older placebo trial supports three-month glycemic efficacy (PMID18397984). Common antibiotic pretreatment, short duration, product standardization and predominantly Chinese trial settings limit generalization. Unique mechanism and clinical complication benefit are not established.

**Rank 2: Metabolic engagement is multiple and does not establish class equivalence (Γ).** Gut, receptor, mitochondrial and secretion pathways may contribute differently depending on exposure and biological context; engagement does not predict universal weight or clinical outcome effects. KCNH6 knockout and acute human clamp results (PMID34556670), SIRT3/model perturbations (PMID30117113), and a nontransferable microbiome result (PMID33994854) support multiple routes; the large obesity trial shows lipid markers can improve while adiposity and glycemia remain null (PMID41543854). No experiment isolates a unique chronic human T2D mediator. Opposite acute islet secretion effects (PMID29467344,18511510) challenge unconditional secretion accounts; genotype/system transfer retains Γ.

**Rank 3: Comparator, co-medication and product context inflate broad claims (Γ).** Some apparent treatment magnitudes or broad cardiometabolic benefits reflect background improvement, bundles, product differences and active-comparator interpretation. PREMOTE placebo HbA1c fell 0.59 percentage points; berberine/cinnamon and multinutraceutical trials change more than one ingredient (PMID39998703,34371883), and metformin comparison is a small pilot (PMID18442638). This cannot explain away PREMOTE's randomized incremental ordinary-berberine effect. It is a source-specific explanation of overextended effect sizes rather than evidence that all efficacy is confounded.

**Rank 4: Exact stack synergy improves clinical outcomes (Α).** A defined combination of berberine, glutathione and NMN produces net clinical benefit beyond its individual ingredients. Separate oral glutathione target engagement (PMID24791752), NMN muscle insulin sensitivity (PMID33888596), and GlyNAC functional signals (PMID35975308) provide ingredient-level motivation. None tests the exact triple stack; GlyNAC is a precursor combination, and some NMN primary/functional outcomes are null (PMID38789831,36740954). Ingredient plausibility cannot establish combination synergy or chronic net safety.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

## FULL REVIEW

### Registered claim and scope

Oral berberine improves glycemic control in adults with type 2 diabetes.

The precise lead clinical proposition is SC2. Mechanism, competing-cause, generalization and safety companions remain separately reported; they do not replace the primary clinical endpoint.

Selection: position 16 in the registered editorial traffic-priority list; registration timestamp 2026-10-13T16:06:25.540258+00:00. Ranked editorial traffic priority rather than measured global popularity or a preset verdict. Registered claim assessed against original sources; no independent blinded calibration is claimed.

### Evidence and causal interpretation

Rubric fit: The frozen framework has no clinical endocrine-treatment rubric. Rubric 06 lifespan/healthspan criteria are quoted unchanged. An explicit clinical-phenotype adaptation treats HbA1c together with glucose measures as the registered glycemic-control phenotype, rather than requiring a lifespan experiment for a diabetes-treatment question. This is not a claim that HbA1c is a hard cardiovascular endpoint. Literal marker caps still govern downstream complication, functional, mortality, aging and mechanism-mediation inferences. Directly measured human clinical glycemia is not re-capped for studying only humans or for being measured in blood.

The lead question concerns adult T2D glycemic treatment. It does not ask whether berberine reproduces prescription GLP-1 outcomes, prevents cardiovascular events or validates a rejuvenation stack. Product composition matters: ordinary berberine, berberine ursodeoxycholate, Berberis fruit extracts and goldenseal are different exposures. HbA1c is assessed as the registered glycemic-control phenotype, with hard clinical outcomes kept separate.

PREMOTE randomized 409 drug-naive patients at 20 Chinese centers after common one-week gentamicin pretreatment. Original Methods verify concealed, blinded assignment and industrially synthesized berberine 1.2g/day for 12 weeks. 391 participants contributed to the primary analysis. HbA1c fell 0.99 percentage points with berberine and 0.59 with placebo, an incremental difference of about 0.40. More GI adverse effects occurred. Probiotics did not improve HbA1c beyond placebo, and adding them did not improve HbA1c beyond berberine (PMID33024120). The common antibiotic background limits transportability without removing the internal randomized comparison.

The older 116-person placebo-controlled T2D/dyslipidemia study reported a significant three-month HbA1c/glucose effect; its insulin-disposal contrast was nonsignificant between groups despite a significant within-arm increase (PMID18397984). The 36-person metformin pilot and 48-person uncontrolled add-on component support feasibility but cannot demonstrate modern class equivalence or isolate the add-on effect (PMID18442638). The related metabolomic report is conservatively grouped and does not supply an independent efficacy trial (PMID20298851). PREMOTE's 365-person postprandial lipid follow-up is the same parent cohort; lipid synergy does not overturn its HbA1c probiotic null (PMID34923903).

The 2025 BUDCA trial randomized 113 T2D adults for 12 weeks. Actual Results give placebo-adjusted HbA1c changes of -0.4 and -0.7 percentage points by dose; weight remained stable (PMID40029660). The molecule combines berberine and ursodeoxycholic acid, so this is a valid different-formulation result rather than proof about every ordinary berberine product. An 18-week presumed NASH/T2D trial and 28-day phaseIb study likewise retain their actual composition and follow-up (PMID34535644,42249406). Cinnamon, fenugreek and hesperidin/chromium bundles lack single-component controls (PMID39998703,35999562,34371883).

The large 2026 diabetes-free obesity/MASLD trial randomized 337 participants for six months and was null for visceral fat, liver fat, body composition and glycemic measures, despite small LDL, apoB and CRP reductions (PMID41543854). Original Methods disclose an active berberine run-in that excluded intolerant or poorly adherent people, narrowing its safety interpretation. This is an important challenge to broad weight-loss extrapolation, while baseline diabetes was excluded and the trial therefore does not falsify the exact T2D lead. An eight-week prediabetes HIIT experiment found no additional benefit from berberine (PMID39107107).

Mechanistic studies provide real but multiple explanations. KCNH6 loss abolished acute mouse berberine effects while another secretagogue remained active; a single-dose healthy-male clamp increased second-phase insulin secretion (PMID34556670). The attached correction 34716337 changes an author-name spelling only. Other models support mitochondrial/SIRT3, gut absorption, BCAA or CypD mechanisms, and rat-islet experiments sometimes inhibit secretion depending on glucose and timing (PMID30117113,26174047,30422704,32770172,29467344,18511510). A derived proteomic/hormone signature MR links a response pattern to IHD/diabetes, but does not instrument assigned oral drug exposure or demonstrate a randomized event benefit (PMID41882153).

Separate ingredient evidence cannot be added into a stack trial. Oral glutathione increases stores (PMID24791752), NMN increases blood NAD and sometimes selected functional outcomes, while primary stepping, physical performance and insulin sensitivity results can be null (PMID38789831,36740954). GlyNAC is a glycine/NAC precursor combination with small functional-trial support, not direct glutathione plus berberine and NMN (PMID35975308). Human CYP and cyclosporin studies show clinically relevant interaction potential (PMID21870106,16541194), supporting careful exposure-specific safety questions rather than a blanket claim of either universal harm or universal safety.

## HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

### Subclaim matrix and aggregation

| Subclaim | Scope | Level | Decision |
|---|---|---|---|
| SC1 Berberine exposure engages candidate metabolic pathways. | Product composition, dose and baseline diabetes measured | Γ | Exposure and candidate pathway engagement are supported by human PK, the acute healthy-human KCNH6 clamp, PREMOTE microbial/metabolite analyses and causal perturbations in mice and cells. These demonstrate plausible multiple routes, but do not isolate a unique endogenous mechanism for chronic human T2D benefit. Model specificity and biomarker-to-human mediation inferences remain Γ; the actual drug treatment effect is scored separately. |
| SC2 Oral berberine improves HbA1c and clinical glycemic control against a credible comparator. | Adults with baseline type 2 diabetes; at least 12 weeks; co-medication fixed | Δ | PREMOTE provides a verified twelve-week, concealed, double-blind placebo comparison in drug-naive T2D adults with synthesized berberine 1.2g/day. HbA1c fell by 0.99 versus 0.59 percentage points; the incremental effect is approximately 0.40 percentage points rather than the entire within-arm fall. The older 116-person placebo-controlled three-month trial also supports a glycemic effect. With the explicit clinical-phenotype adaptation, these positive randomized comparisons cross Δ for the registered glycemic-control phenotype. Durable treatment effects across the full range of baseline T2D, products and co-medication have not been mapped. Diabetes-free adiposity nulls do not manufacture an Ε boundary within the registered T2D scope. |
| SC3 Berberine is clinically equivalent to modern GLP-1 medicines for weight loss and cardiometabolic outcomes. | Direct molecule, exposure and outcome matched comparison | Α | No examined direct, matched, powered noninferiority comparison establishes berberine equivalence to modern GLP-1 medicines for weight loss or cardiometabolic outcomes. Metformin pilot similarity, short antipsychotic-weight studies and BUDCA biomarker effects are different interventions or contexts. The large six-month diabetes-free obesity trial was null for visceral and liver fat and body composition. Exact class-equivalence claims remain Α, without treating absence of a direct comparison as proof of inferiority on every outcome. |
| SC4 Berberine, glutathione and NMN combination stacks have established net clinical benefit. | Exact combination and functional or clinical outcome specified | Α | No examined trial tests the exact berberine, glutathione and NMN combination with clinical or functional net benefit and component-dismantling controls. Ingredient-specific NAD, glutathione and short functional findings are real but do not establish a triple-stack interaction or long-term safety. Exact stack-benefit claims remain Α; this does not negate separate ingredient effects. |

Preregistered aggregation: primary-subclaim. The preregistered primary-subclaim rule returns Δ from SC2: defined oral berberine has a positive controlled treatment effect on twelve-week T2D glycemic control. The claim is deliberately narrower than weight loss, GLP-1 equivalence, complication prevention or rejuvenation stacks. Sixty-three original reports include clinical efficacy, exposure and interaction studies, relevant model experiments and companion ingredients; they are not sixty-three isolated T2D efficacy trials. Weakest-link returns Α because the separate equivalence and exact-stack companions lack direct evidence; primary-subclaim and scope-matched return Δ. Repeated trials increase confidence but do not automatically become independently failing causal lines or identify a unique mediator. Sensitivities: weakest-link Α; primary-subclaim Δ; scope-matched Δ.

### Decisive-perturbation inventory and causal tally

[1] PREMOTE randomized drug-naive newly diagnosed T2D patients to synthesized berberine 1.2g daily or matched placebo for 12 weeks after common gentamicin pretreatment; original Methods verify concealed age-stratified allocation and blinding. HbA1c reduction -0.99 vs -0.59 percentage points; more GI adverse events. Original Results 391/409 primary-analysis participants; probiotic addition did not improve HbA1c. Observed treatment effect is conditional on this antibiotic/lifestyle background and duration; microbial covariance does not prove unique human mediation or long-term complication benefit.

[2] Distinct HTD1801 berberine-ursodeoxycholate formulation 113 randomized T2D patients for 12 weeks; original Methods/Results confirm matched placebo and placebo-adjusted HbA1c -0.4/-0.7 percentage points by dose; weight remained stable. BUDCA is a new combined molecular entity; benefit cannot be assigned to ordinary berberine alone or borrowed for GLP1 weight-loss equivalence. No cardiovascular event endpoint.

[3] 116 T2D/dyslipidemia patients randomly allocated berberine 1g daily or placebo for 3 months; HbA1c 7.5 to 6.6 and fasting/postload glucose improvements differed significantly from placebo; constipation in 5. Within-arm change is not the treatment difference; clamp disposal change did not differ significantly between arms P=.063. Abstract-level access does not verify every allocation/adherence detail or hard outcomes.

[8] 31 T2D participants randomized 3 months to Berberis fruit extract 3g daily or placebo; glucose/insulin and lipid effects positive while HbA1c showed no significant between-arm change. Fruit extract is multicomponent and dose not equivalent to isolated berberine; this null HbA1c does not falsify the pure-drug exposure hypothesis.

[9] Study A 36 newly diagnosed T2D adults randomized berberine versus metformin for 3 months with similar glycemic reductions; Study B 48 poorly controlled adults added berberine and HbA1c fell; GI effects 34.5% across reported patients. Active-comparator pilot was not a powered noninferiority demonstration; uncontrolled add-on StudyB cannot isolate treatment effect. Metformin similarity is not modern GLP1 equivalence.

[34] Original M/R verify global and beta-cell Kcnh6 knockout abolished acute berberine glucose/insulin effect while tolbutamide remained active; 15 healthy men single-dose crossover clamp showed second-phase secretion increase. Animal 560mg/kg acute drug dependence plus healthy clamp does not establish endogenous human 12 week T2D mediation or GLP1 equivalence. Attached 34716337 corrects an author-name typo only.

[40] Original Methods/Results: 337 diabetes-free obese MASLD participants randomized 6 months 1g/day berberine or matching placebo after tolerance/adherence run-in; VAT, liver fat, body composition and HbA1c effects null despite modest LDL/apoB/CRP reduction. Excludes diabetes and selects tolerant adherers; does not refute T2D glycemic efficacy or establish all-comer safety. Strong boundary against broad adiposity and biomarker-to-weight extrapolation.

[63] 54 overweight prediabetic men randomized 6 groups 8 weeks HIIT/berberine combinations; exercise benefited glucose/IR, adding berberine did not add benefit; berberine-only within-arm changes. Prediabetes label with unusually broad 110–180mg/dL FBG reported and 8 weeks outside registered eligibility; within-arm change not treatment contrast. No GLP1 head-to-head.

Tally: 2 positive qualifying study units across scoped subclaims; 2 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Two positive ordinary-berberine clinical study units supply SC2 threshold credit; this is not two independently failing lines or sixty-three clinical efficacy trials. BUDCA, botanical extracts, bundles, prediabetes, PCOS, obesity and acute healthy-human studies remain separate scopes. PREMOTE follow-up, related metabolomics, correction notices and provider citations do not inflate trial independence or examined-original counts. Ingredient-specific clinical signals do not count as positive exact triple-stack perturbations.

### Cap audit, precedence and Β/Γ/Δ boundary

Literal rubric 06 aging thresholds are preserved and disclosed, while the preregistered clinical adaptation assesses the actual diabetes-treatment phenotype. HbA1c plus glucose control can cross the clinical threshold without a lifespan trial. The marker cap still binds inference to cardiovascular events, functional improvement, longevity or unique mediation. Positive mouse pathway dependency crosses within its actual model but does not automatically become chronic human dependency. A derived MR signature is considered on its assumptions without being equated to an instrument of oral drug exposure; no weak-leg cap is reapplied to a genuinely convergent exact-scope set.

Universal six-cap audit: All six universal caps were considered: cell-only inference, unperturbed association, ectopic expression, biomarker-only intervention, forced transfer/seeding, and inherited-to-sporadic scope transfer. Each binds its offered inference; complementary same-scope causal classes are assessed together rather than re-capped in isolation.

Gamma hard-rule audit: Target engagement, NAD and antioxidant stores do not substitute for a clinical glycemic phenotype or durable functional outcome. The direct registered HbA1c/glucose phenotype is distinguished from downstream cardiovascular events and aging; the clinical adaptation does not remove the literal marker cap from those inferences. BUDCA, fruit extracts, goldenseal and multinutraceutical formulas retain their actual composition. Positive randomized efficacy and unresolved unique mediation are distinct decisions.

SC1 cap: “Biomarker change without functional/phenotypic change caps at Γ.” Exposure and candidate pathway engagement are supported by human PK, the acute healthy-human KCNH6 clamp, PREMOTE microbial/metabolite analyses and causal perturbations in mice and cells. These demonstrate plausible multiple routes, but do not isolate a unique endogenous mechanism for chronic human T2D benefit. Model specificity and biomarker-to-human mediation inferences remain Γ; the actual drug treatment effect is scored separately.

SC3 cap: “Use when the hypothesis is mostly a grand narrative with weak intervention support.” No examined direct, matched, powered noninferiority comparison establishes berberine equivalence to modern GLP-1 medicines for weight loss or cardiometabolic outcomes. Metformin pilot similarity, short antipsychotic-weight studies and BUDCA biomarker effects are different interventions or contexts. The large six-month diabetes-free obesity trial was null for visceral and liver fat and body composition. Exact class-equivalence claims remain Α, without treating absence of a direct comparison as proof of inferiority on every outcome.

SC4 cap: “Use when the hypothesis is mostly a grand narrative with weak intervention support.” No examined trial tests the exact berberine, glutathione and NMN combination with clinical or functional net benefit and component-dismantling controls. Ingredient-specific NAD, glutathione and short functional findings are real but do not establish a triple-stack interaction or long-term safety. Exact stack-benefit claims remain Α; this does not negate separate ingredient effects.

SC1 field-valid definition: “
- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension
- Must separate developmental effects from true aging effects
- Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Exposure and candidate pathway engagement are supported by human PK, the acute healthy-human KCNH6 clamp, PREMOTE microbial/metabolite analyses and causal perturbations in mice and cells. These demonstrate plausible multiple routes, but do not isolate a unique endogenous mechanism for chronic human T2D benefit. Model specificity and biomarker-to-human mediation inferences remain Γ; the actual drug treatment effect is scored separately.

SC2 field-valid definition: “
- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension
- Must separate developmental effects from true aging effects
- Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. PREMOTE provides a verified twelve-week, concealed, double-blind placebo comparison in drug-naive T2D adults with synthesized berberine 1.2g/day. HbA1c fell by 0.99 versus 0.59 percentage points; the incremental effect is approximately 0.40 percentage points rather than the entire within-arm fall. The older 116-person placebo-controlled three-month trial also supports a glycemic effect. With the explicit clinical-phenotype adaptation, these positive randomized comparisons cross Δ for the registered glycemic-control phenotype. Durable treatment effects across the full range of baseline T2D, products and co-medication have not been mapped. Diabetes-free adiposity nulls do not manufacture an Ε boundary within the registered T2D scope.

SC3 field-valid definition: “
- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension
- Must separate developmental effects from true aging effects
- Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. No examined direct, matched, powered noninferiority comparison establishes berberine equivalence to modern GLP-1 medicines for weight loss or cardiometabolic outcomes. Metformin pilot similarity, short antipsychotic-weight studies and BUDCA biomarker effects are different interventions or contexts. The large six-month diabetes-free obesity trial was null for visceral and liver fat and body composition. Exact class-equivalence claims remain Α, without treating absence of a direct comparison as proof of inferiority on every outcome.

SC4 field-valid definition: “
- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension
- Must separate developmental effects from true aging effects
- Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. No examined trial tests the exact berberine, glutathione and NMN combination with clinical or functional net benefit and component-dismantling controls. Ingredient-specific NAD, glutathione and short functional findings are real but do not establish a triple-stack interaction or long-term safety. Exact stack-benefit claims remain Α; this does not negate separate ingredient effects.

SC1 applied rubric adaptation (distinct from the unchanged literal criterion): Candidate target engagement is distinct from human chronic mediation. Physiological channel dependence in mice and acute healthy-human insulin secretion cannot isolate the clinical T2D pathway; marker and system-transfer limits remain explicit.

SC2 applied rubric adaptation (distinct from the unchanged literal criterion): The field-valid clinical equivalent is randomized oral defined berberine versus a credible retained comparator in adults with baseline T2D for at least twelve weeks, with fixed background medication and positive HbA1c/glucose control. HbA1c is the preregistered treatment phenotype; cardiovascular events, quality of life, complications and longevity remain separate outcomes. Common gentamicin run-in is disclosed rather than treated as a hidden unbalanced confounder.

SC3 applied rubric adaptation (distinct from the unchanged literal criterion): Clinical equivalence requires direct molecule/exposure/outcome-matched noninferiority trials against modern GLP-1 medicines. An acute endogenous GLP-1 signal, metformin similarity or different-formulation HbA1c change is not such a trial.

SC4 applied rubric adaptation (distinct from the unchanged literal criterion): Exact triple-stack net clinical benefit requires the defined combination, clinical/function readouts, sufficient safety follow-up and component controls. Separate NMN, direct glutathione, GlyNAC and berberine-containing bundles cannot be summed into a combination result.

SC1 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Single-species or single-strain evidence” Triggered for mouse-to-human mechanism transfer; the human acute clamp establishes secretion physiology but not chronic human T2D mediator dependence.

SC1 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Triggered for inferring a necessary clinical mediator from insulin-receptor, BCAA, bile-acid, NAD or inflammatory marker change alone.

SC2 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered for directly studied human glycemic-treatment outcomes; animal generalization is not being used to supply this clinical crossing.

SC2 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered for the explicitly registered glycemic-control phenotype itself under the documented clinical adaptation. Triggered for any inference from that phenotype to reduced cardiovascular events, complications, general function or longevity, which are not claimed by the Δ decision.

SC3 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “NAD level change measurements alone” Triggered for extrapolating NMN target engagement to clinical benefit; it is not evidence that the exact triple stack was tested.

SC4 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Triggered for ingredient-derived clinical/longevity extrapolation from blood NAD or glutathione stores.

### Upward threshold ladder

SC1 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Use exposure-matched human or disease-relevant mediator dissociation/rescue to identify a chronic T2D pathway separately from treatment efficacy, accounting for pathway compensation and multiple routes.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes. 

SC2 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: no. Prespecify tests across baseline T2D severity, co-medication and product contexts with adequate duration and verified ordinary-berberine exposure. A mapped in-scope positive/null boundary would support Ε; an independently failing exact-phenotype causal line would be needed for Ζ.

SC3 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Conduct powered direct modern GLP-1 noninferiority trials with prespecified margins for weight, clinical outcomes, adherence, tolerability and follow-up; indirect biomarker resemblance cannot cross the equivalence threshold.

SC4 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Test the exact triple stack against placebo and single-/dual-component arms with prespecified clinical/function outcomes and sufficient interaction/safety follow-up; target engagement alone cannot demonstrate net benefit.

Upper ladder: Replicated oral-drug RCTs were considered but share pharmacologic exposure, product, adherence and comparator failure possibilities. The derived signature MR (PMID41882153) is informative yet genetically perturbs a response-associated protein/hormone pattern rather than assigned oral berberine; it does not independently establish the exact twelve-week T2D phenotype. Mouse knockout and human acute secretion constrain mechanisms but do not provide an independent chronic clinical causal line. No convergence is denied merely because one component is observational; the exact-scope independently failing conjunction is unverified.

Independence: No model or subclaim reaches Ζ. PREMOTE secondary lipids are one parent; related metabolomics are conservatively grouped; replicate drug trials are not automatically new independently failing modalities. Different model targets do not become additional clinical lines solely by measuring a new molecule. A genuine exact-exposure natural experiment or independently identifying mediator perturbation could exclude distinct systematic errors.

### Falsification and pitfalls

Therapeutic effect misread as mechanistic proof. Randomized HbA1c benefit demonstrates a treatment effect, not unique microbiome, AMPK, insulin-receptor or KCNH6 mediation.

Confirmation by biomarker. Blood NAD, glutathione, LDL and predicted-risk movement cannot substitute for stack function, cardiovascular events or longevity.

Mechanism conflation. Ordinary berberine differs from BUDCA, fruit extract, goldenseal and berberine/cinnamon bundles; endogenous GLP-1 signaling does not establish prescription GLP-1 equivalence.

Scope fitted to the result. Diabetes-free obesity nulls are outside baseline T2D; tolerant-run-in selection and completer analyses do not justify universal all-comer safety or responder-defined benefit.

Replication confused with reproduction. PREMOTE lipid follow-up is the same parent trial; related metabolomic reports and reused signatures do not add independent drug efficacy lines.

Association dressed as mechanism. Microbial or metabolite covariance and a genetically instrumented drug-response signature do not directly perturb assigned oral exposure or prove clinical event mediation.

### Adversarial steelman: above, then below

The strongest Ε case combines replicated positive placebo trials with null results in diabetes-free obesity and prediabetic exercise settings, suggesting baseline metabolic context determines efficacy. PREMOTE's matched probiotic controls and distinct mechanistic studies further narrow explanations. This is a substantial argument for context-specific effects in the broader topic family.

The strongest Γ case applies the literal aging-rubric biomarker-only rule to HbA1c and points to short studies, antibiotic pretreatment and unresolved mediation. That case would be persuasive for cardiovascular protection, rejuvenation or a unique mechanism inferred from glycemic markers. It is less persuasive for the preregistered treatment phenotype itself.

The higher case is rejected for the exact lead: diabetes-free/preclinical nulls do not map a failure boundary inside baseline T2D, and chronic product/co-medication/duration generalization remains largely untested. The lower case is rejected because the clinical adaptation was explicit before outcome appraisal, and a verified concealed placebo trial directly improves the registered glycemic phenotype. The decision does not extend Δ to hard complications, longevity or unique endogenous mediation.

### Final score, causal direction and M/S/D

The preregistered primary-subclaim rule returns Δ from SC2: defined oral berberine has a positive controlled treatment effect on twelve-week T2D glycemic control. The claim is deliberately narrower than weight loss, GLP-1 equivalence, complication prevention or rejuvenation stacks. Sixty-three original reports include clinical efficacy, exposure and interaction studies, relevant model experiments and companion ingredients; they are not sixty-three isolated T2D efficacy trials. Weakest-link returns Α because the separate equivalence and exact-stack companions lack direct evidence; primary-subclaim and scope-matched return Δ. Repeated trials increase confidence but do not automatically become independently failing causal lines or identify a unique mediator.

For the beneficial glycemic-control trajectory, positive randomized ordinary-berberine versus placebo treatment demonstrates a causal contribution, so the no-dependency Step 2 does not apply. Neither necessity/primacy nor a required permissive condition is demonstrated. Step 5 therefore describes an exposure that reinforces or stabilizes glycemic control in established T2D. This therapeutic direction does not imply that berberine reinforces diabetes or that one candidate endogenous pathway initiates the disease.

Momentum: Mechanistic only. Recent KCNH6, response-signature and formulation studies examine mechanisms or different products (PMID34556670,41882153,40029660). BUDCA trials cannot be silently substituted for a verified pending ordinary-berberine long-term glycemic result.

Stability: Stable. No verified named pending exact ordinary-berberine result was identified that determines the full-scope letter. A prespecified durable T2D placebo trial across baseline treatment contexts is a concrete upward/generalization trigger; existing BUDCA development is distinct.

Divergence: Contested. Required artifact: the two framings carry different implied levels, so no single implied level and no arithmetic gap can be stated. Consumer and supplement-channel framing presents the compound as interchangeable with prescription GLP-1 medicines and as a broad weight-loss and rejuvenation agent, which would imply a level well above the assessed Δ for SC3 and SC4; the controlled-trial literature cited here presents a modest short-term HbA1c effect of uncertain durability, which is approximately aligned with Δ for SC2. No manufactured field consensus is asserted. These dimensions do not change level or confidence.

## PROPOSED DECISIVE EXPERIMENTS

Run a multisite, baseline-stratified, double-blind trial of chemically verified ordinary oral berberine versus matching placebo added to unchanged standard T2D care, with prespecified twelve-month glycemic durability and adverse-event outcomes. Include strata for baseline HbA1c, disease duration and fixed co-medication; avoid routine antibiotic pretreatment or randomize that factor separately if mechanistically essential. Add prespecified pathway measurements and an orthogonal mediator-dissociation component rather than declaring correlated microbiome changes necessary. Evaluate GLP-1 equivalence and the exact triple stack in separate properly controlled trials.

Readout: HbA1c and continuous/fasting glucose treatment contrasts, hypoglycemia, GI tolerability, adherence, interactions, medication rescue and durability; hard complications assessed separately if powered. Controls: Matching placebo, concealed allocation, verified product/dose, stable background care, prespecified baseline strata, blinded laboratory measurements and complete intention-to-treat follow-up. Supporting: Durable incremental clinical glycemic benefit across prospectively defined T2D contexts with acceptable safety; mediator dissociation independently narrows mechanism. Falsifying: No incremental glycemic effect despite verified exposure and adherence, or benefit explained by unequal rescue/co-medication; harms or durable loss of effect retained in the analysis.

## KNOWLEDGE GAPS

Durable ordinary-berberine efficacy and safety beyond short T2D trials under contemporary unchanged standard care

Role of common antibiotic pretreatment and baseline microbial ecology in the PREMOTE response

Exposure/product standardization and translation between ordinary berberine, BUDCA and botanical bundles

Unique chronic human mediation versus simultaneous gut, secretion, receptor and mitochondrial effects

Direct modern GLP-1 equivalence for specified weight and cardiometabolic outcomes

Exact triple-stack trials and component-dismantling evidence with meaningful functional outcomes

Drug interactions, formulation variability and all-comer tolerability beyond selected short-term cohorts

## REVIEWER NOTES

Sixty-three primary reports were actually presented and individually appraised. Most access is complete original abstract/status presentation within the bounded limit; selected Methods/Results were checked for PREMOTE, BUDCA2025, diabetes-free obesity 2026 and KCNH6. The KCNH6 author-name correction was separately checked and is not counted as a primary report. The older Yin 2008 public XML retrieval returned 500 and was not credited as body reading. Consensus observed-browser reconciliation is added separately, with provider counts distinct from original examination. No full-paper/supplement audit, independent blinded calibration or scientific peer review is claimed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

## Consensus and original-source reconciliation

Consensus accurately identified the common seven-day gentamicin run-in and within-arm HbA1c changes. Original Methods/Results verify concealed double-blind allocation, drug-naive baseline T2D and synthesized 1.2g/day berberine for 12 weeks. The treatment contrast is approximately 0.40 percentage points beyond placebo, not the entire 0.99-point fall. 391 of 409 contributed to the primary analysis. Microbial/metabolite associations do not establish uniquely necessary human mediation. The provider's 100% meter across 11 items is neither a probability that this mechanism is true nor an examined-original count. [Original PMID33024120](https://pubmed.ncbi.nlm.nih.gov/33024120/).

Consensus correctly separated lipid synergy from glycemic superiority. The original abstract explicitly identifies 365 participants from PREMOTE, so the report is counted as an original secondary analysis of the same parent trial rather than a new independent glycemic RCT. Its Bifidobacterium/fadD and postprandial lipid findings do not show that probiotics improve HbA1c beyond berberine, and are not cardiovascular event results. [Original PMID34923903](https://pubmed.ncbi.nlm.nih.gov/34923903/).

Consensus accurately reports 36 randomized new-T2D patients and 48 add-on patients. The original abstract distinguishes the active-comparator pilot from the uncontrolled add-on study. Similar changes in the pilot do not demonstrate powered noninferiority, and the whole within-arm HbA1c fall cannot be attributed to the drug without a concurrent comparison. Metformin comparison does not establish modern GLP-1 equivalence. The attempted public XML body retrieval failed; this comparison has abstract/status access only. [Original PMID18442638](https://pubmed.ncbi.nlm.nih.gov/18442638/).

Consensus correctly names HTD1801 as berberine ursodeoxycholate and reports the high-dose placebo-adjusted 0.7-percentage-point HbA1c benefit. Original Methods/Results show 113 randomized T2D patients, 12 weeks and lower-dose 0.4-point effect. Weight remained stable. This is a valid distinct-formulation trial, not isolated ordinary-berberine efficacy or evidence of GLP-1-equivalent weight loss. The approximate trial effect does not establish reduced complications. [Original PMID40029660](https://pubmed.ncbi.nlm.nih.gov/40029660/).

Despite the question naming the 2026 study, the observed Consensus response did not discuss this 337-person ordinary-berberine trial and instead used a different multi-ingredient obesity example. Original Methods/Results verify six-month null effects on visceral fat, liver fat, body composition and glycemic measures, with small lipid/CRP changes. Diabetes was excluded, and an active run-in selected tolerant adherers. This omission matters for broad weight-loss and safety narratives; it does not refute the registered baseline-T2D glycemic effect. [Original PMID41543854](https://pubmed.ncbi.nlm.nih.gov/41543854/).

Consensus accurately reports that Berberis fruit extract improved fasting glucose/lipids but not HbA1c. The original 31-person three-month trial confirms a between-arm HbA1c null. The exposure was 3g/day multicomponent fruit extract, so it is kept as a formulation boundary rather than a pure-berberine T2D null used to erase placebo-controlled drug results. [Original PMID24250489](https://pubmed.ncbi.nlm.nih.gov/24250489/).

Consensus reports normalization of prediabetic markers after 84 days, matching the 34-person pilot abstract. Baseline prediabetes, small sample and branded exposure differ from the registered T2D lead. Moving markers below diagnostic thresholds does not establish prevention of future diabetes, durable remission or complication reduction. [Original PMID37679692](https://pubmed.ncbi.nlm.nih.gov/37679692/).

The question requested KCNH6 and its correction, but the observed provider response did not adjudicate them. Original selected Methods/Results verify acute high-dose global/beta-cell mouse knockout dependence and a single-dose clamp in 15 healthy men, not chronic human T2D pathway necessity. Attached correction 34716337 was actually read and changes only the author-name spelling Tetsuro Izumi. It adds no primary-study count and does not change numerical results. [Original PMID34556670](https://pubmed.ncbi.nlm.nih.gov/34556670/).

Consensus states that dedicated stack trials are lacking. The original glutathione trial shows increased stores in 54 healthy adults after six months, with immune-marker subset results. It tests direct glutathione alone, not berberine/NMN synergy or net clinical benefit. Separate ingredient trials and provider links cannot substitute for an exact combination comparison. [Original PMID24791752](https://pubmed.ncbi.nlm.nih.gov/24791752/).

Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.

## Research timeline and gaps: Berberine and Glycemic Control

Selected publication milestones, not an exhaustive history or discovery priority claim.

**2006 — Human cyclosporin interaction work shows dose-dependent exposure effects, an early constraint on simple supplement-safety claims.** [Original PMID16541194](https://pubmed.ncbi.nlm.nih.gov/16541194/).

**2008 — A three-month placebo-controlled T2D/dyslipidemia trial reports HbA1c and glucose benefit with ordinary berberine.** [Original PMID18397984](https://pubmed.ncbi.nlm.nih.gov/18397984/).

**2008 — The metformin pilot and uncontrolled add-on component motivate clinical research while leaving noninferiority and treatment attribution unresolved.** [Original PMID18442638](https://pubmed.ncbi.nlm.nih.gov/18442638/).

**2008 — Acute secretion inhibition and later cell response show that dose, glucose state and timing matter for mechanism narratives.** [Original PMID18511510](https://pubmed.ncbi.nlm.nih.gov/18511510/).

**2010 — Patient metabolomics proposes free-fatty-acid involvement but is conservatively grouped with related earlier efficacy work.** [Original PMID20298851](https://pubmed.ncbi.nlm.nih.gov/20298851/).

**2012 — Repeated-dose healthy-human CYP probe testing verifies drug-interaction potential rather than assuming inert supplement exposure.** [Original PMID21870106](https://pubmed.ncbi.nlm.nih.gov/21870106/).

**2015 — A direct glutathione trial establishes body-store engagement, providing ingredient context without testing a triple stack.** [Original PMID24791752](https://pubmed.ncbi.nlm.nih.gov/24791752/).

**2015 — Animal microbial conversion/absorption experiments propose an exposure route; broad antibiotic perturbation does not isolate clinical human mediation.** [Original PMID26174047](https://pubmed.ncbi.nlm.nih.gov/26174047/).

**2020 — PREMOTE supplies a verified concealed twelve-week T2D placebo comparison and a separate microbial hypothesis under common antibiotic pretreatment.** [Original PMID33024120](https://pubmed.ncbi.nlm.nih.gov/33024120/).

**2021 — NMN improves measured muscle insulin sensitivity in prediabetic women, a component-specific result without combination evidence.** [Original PMID33888596](https://pubmed.ncbi.nlm.nih.gov/33888596/).

**2021 — Mouse KCNH6 loss and a healthy-human acute clamp narrow a secretion mechanism; the attached correction changes an author name only.** [Original PMID34556670](https://pubmed.ncbi.nlm.nih.gov/34556670/).

**2022 — A PREMOTE lipid secondary analysis illustrates why new mechanistic resolution is not a new independent efficacy trial.** [Original PMID34923903](https://pubmed.ncbi.nlm.nih.gov/34923903/).

**2023 — Short NMN physiology produces NAD and selected risk-factor changes while several functional/metabolic endpoints remain null.** [Original PMID36740954](https://pubmed.ncbi.nlm.nih.gov/36740954/).

**2024 — An older-adult NMN trial has a null primary stepping endpoint alongside selected secondary walking/sleep signals.** [Original PMID38789831](https://pubmed.ncbi.nlm.nih.gov/38789831/).

**2025 — A distinct BUDCA formulation produces dose-related twelve-week T2D HbA1c benefit while weight stays stable.** [Original PMID40029660](https://pubmed.ncbi.nlm.nih.gov/40029660/).

**2026 — A six-month ordinary-berberine obesity/MASLD trial is null for adiposity and glycemic measures in diabetes-free adults, limiting broad weight-loss extrapolation.** [Original PMID41543854](https://pubmed.ncbi.nlm.nih.gov/41543854/).

**2026 — Drug-response signature MR generates cardiometabolic hypotheses without directly instrumenting oral exposure or replacing clinical event trials.** [Original PMID41882153](https://pubmed.ncbi.nlm.nih.gov/41882153/).

## Research gaps

Durable ordinary-berberine efficacy and safety beyond short T2D trials under contemporary unchanged standard care

Role of common antibiotic pretreatment and baseline microbial ecology in the PREMOTE response

Exposure/product standardization and translation between ordinary berberine, BUDCA and botanical bundles

Unique chronic human mediation versus simultaneous gut, secretion, receptor and mitochondrial effects

Direct modern GLP-1 equivalence for specified weight and cardiometabolic outcomes

Exact triple-stack trials and component-dismantling evidence with meaningful functional outcomes

Drug interactions, formulation variability and all-comer tolerability beyond selected short-term cohorts

## Boundary experiment

Run a multisite, baseline-stratified, double-blind trial of chemically verified ordinary oral berberine versus matching placebo added to unchanged standard T2D care, with prespecified twelve-month glycemic durability and adverse-event outcomes. Include strata for baseline HbA1c, disease duration and fixed co-medication; avoid routine antibiotic pretreatment or randomize that factor separately if mechanistically essential. Add prespecified pathway measurements and an orthogonal mediator-dissociation component rather than declaring correlated microbiome changes necessary. Evaluate GLP-1 equivalence and the exact triple stack in separate properly controlled trials.


## ADVERSARIAL REVIEW AND APPROVAL

**Authoring model:** Sol 6.1. **Adversarial reviewer:** Claude Opus 5.5 (Anthropic). **Date:** 2026-10-14.

**Scope of checks.** All 63 REFERENCES PMIDs were verified against PubMed metadata for title, first author, journal, year and DOI: 63/63 resolve to the stated record, 0 failures, and no retraction or expression-of-concern flag appears on any record. Twelve load-bearing claims were spot-checked against the primary abstracts: PREMOTE enrollment, centre count, gentamicin run-in, dose, duration and the -0.99 versus -0.59 percentage-point HbA1c contrast (PMID 33024120); the 116-person three-month trial's HbA1c 7.5 to 6.6 fall, between-arm clamp P = .063 and constipation in five participants (PMID 18397984); the BUDCA 113-patient randomization and the -0.4 and -0.7 placebo-adjusted dose effects (PMID 40029660); the Kcnh6 knockout abolition of the acute effect and the 15-man single-dose clamp (PMID 34556670); the 31-patient Berberis fruit-extract HbA1c null at 3 g/day (PMID 24250489); study A (36 patients) versus study B (48 patients) and the 34.5% gastrointestinal rate (PMID 18442638); the 365-participant PREMOTE lipid secondary analysis (PMID 34923903); the 54-adult six-month oral glutathione trial (PMID 24791752); the null primary stepping endpoint with secondary walking and sleep signals (PMID 38789831); muscle insulin sensitivity in prediabetic women (PMID 33888596); the 337-participant diabetes-free obesity and MASLD null for visceral and liver fat alongside LDL, apoB and hs-CRP reductions (PMID 41543854); and the 54-man six-group eight-week HIIT trial with fasting glucose 110-180 mg/dL in which berberine added no benefit (PMID 39107107). All twelve matched the review. Scoring logic was re-derived independently of the recorded letter: cap order and precedence, the preregistered primary-subclaim aggregation and its reported alternatives, the five Beta/Gamma/Delta boundary clauses, the Delta-versus-Epsilon mapped-boundary test, the Zeta independence test, and the Momentum, Stability and Divergence artifacts. The framework validator was re-run after editing.

**Findings.**

| ID | Severity | Location | Original to corrected | Evidence |
|---|---|---|---|---|
| A1 | Minor | Throughout: evidence and causal interpretation, subclaim matrix, decisive-perturbation inventory, evidence cards, Consensus reconciliation | About 230 instances of the known builder rendering defect, with numerals fused to the preceding word ("randomized409", "for12weeks", "fell0.99", "placebo-adjusted0.7") and words fused to one another ("benefitedglucose", "addingberberine", "Prediabeteslabel", "registeredeligibility", "headtohead", "VAT,liver fat,bodycomposition"), corrected by restoring the spaces. No number, direction or claim was altered. | Round-2 brief, known upstream defect 4 (missing spaces around numerals) |
| A2 | Minor | Evidence card for the goldenseal and metformin interaction study | "aggregate metforminAUC ratio.93" corrected to "aggregate metformin AUC ratio 0.93" | PubMed PMID 39943692 reports a metformin AUC geometric mean ratio of 0.93 with a 90% confidence interval of 0.86 to 1.01, inside the predefined no-effect range of 0.80 to 1.25. The dropped leading zero left the reported ratio unreadable as a number. |
| A3 | Editorial | REFERENCES item 8 | "DOI: ." corrected to "DOI: none indexed." | Known upstream defect 4 (empty DOI field). PubMed indexes no DOI for PMID 24250489, so the empty field was correct in substance but rendered as a defect. |
| A4 | Minor | Final score, causal direction and M/S/D in the prose, and the divergence justification in the score card | "Divergence: Contested. No manufactured field consensus or arithmetic gap." replaced by the same verdict carrying its required artifact: the two competing framings and why no single implied level applies | Framework, Divergence: "Required artifact: state the implied level and the arithmetic." Contested is the one value for which no single implied level exists, so the artifact is the named split. The score card already carried an implied-level basis; the prose did not. Verdict, level and confidence unchanged. |
| A5 | Editorial | Rubric-fit note and cap audit | "Rubric06" and "rubric06" corrected to "Rubric 06" and "rubric 06" | Same rendering-defect class as A1 |
| A6 | Major | AT A GLANCE, "Best-supported rival" | The line named the nominal model itself, "Defined berberine has a glycemic treatment effect", as the best-supported rival. Replaced with the highest-ranked model other than the nominal, "Metabolic engagement is multiple and does not establish class equivalence", with the PREMOTE contrast retained where it belongs | Renderer defect: the line prints `competing_models.models_evaluated[0]`, and in this score card that entry is M1 with `is_nominal: true` and `rank_in_tournament: 1`. The framework's AT A GLANCE block requires the best-supported rival, which cannot be the nominal. The tournament ranking, the level and the confidence are unchanged; only the mislabelled line is corrected. |
| A7 | Minor | Score card `final_score.confidence_rationale` | "density, heterogeneous controls and incomplete access set the confidence" corrected to drop access depth as a determinant and to record the re-test against the High band | Framework, Confidence band: "Confidence reflects evidence density and reproducibility." The reviewer's own read depth is not a property of the evidence. The band was then re-tested against the High text, "extensive independent replication across labs, models, and assay modalities", and holds at Moderate for the reasons given in the rationale. No band change. |

**Rejected findings (checked, no change).**

1. Reference years differing from the PubMed e-publication year by one: PMID 19800084 (printed 2010, e-pub 2009), 22019891 (2012 and 2011), 23869585 (2014 and 2013), 34773803 (2022 and 2021). Rejected under the citation-year convention.
2. HbA1c treated as the registered glycemic-control phenotype rather than as a capped biomarker. Checked against universal cap 4, "Biomarker change without functional/phenotypic change caps at Gamma", and against the review's declared clinical-phenotype adaptation, which keeps the literal cap binding on complication, functional, mortality and mechanism-mediation inferences. The registered claim concerns glycemic control, and HbA1c with concurrent glucose measures is that phenotype rather than a surrogate for it. Defensible; the Delta crossing stands.
3. Delta rather than Epsilon. The framework requires a mapped context boundary for Epsilon and leaves untested generalization at Delta. The diabetes-free obesity and MASLD null (PMID 41543854) excluded baseline diabetes and therefore lies outside the registered scope, so it does not map a failure boundary inside it. No change.
4. Delta rather than Zeta. The replicate placebo-controlled oral-berberine trials share pharmacologic exposure, product and adherence failure modes, so under the shared-failure independence test they are one causal line rather than two. No change.
5. Role of mechanism "reinforcing / stabilizing factor". The direction-of-causation procedure is written for a disease mechanism and fits a therapeutic exposure awkwardly; the review says so and falls through to step 5. A defensible judgement call, not an error.
6. Stability "Stable" while a future durable trial is described. Correct as written: the framework defines Stable as the answer when no pending result can be named, and the trial described is a proposal rather than a pending readout.
7. Momentum "Mechanistic only". The required artifact is present and names specific work (PMID 34556670, 41882153, 40029660), so the momentum-boilerplate defect flagged for this round does not apply.
8. Collective-author reference defect, in which a consortium first author renders as a leading comma. Searched; none present.
9. Absence of a v5.4 lay summary. The package is built against a frozen v5.3 framework and declares it, so this is not an error against its own contract.

10. Whether the confidence band should move to High once access depth is removed as a determinant. Re-tested against the framework text: the review's own tally is two positive ordinary-berberine clinical study units, concentrated in short trials with heterogeneous products and a largely single-country setting, which is the Moderate text rather than the High text. The band holds at Moderate. The superseded wording is preserved in the dated audit snapshots in this folder by design.
11. The coordinator-flagged Consensus-splice artifacts do not apply: this case is not one of the 2026-10-09 revised editions, carries no spliced provenance block and no "earlier adversarial approval" clause.

**Residual limitations.** Access is four partial-body and fifty-nine bounded abstract or status examinations, so figures attributed to Methods and Results sections that the abstracts do not reproduce - the 391 of 409 primary-analysis count, the age-stratified allocation, the active berberine run-in in PMID 41543854, and the 560 mg/kg mouse dose and tolbutamide control in PMID 34556670 - were checked for internal consistency but could not be confirmed against a complete paper in this pass. No independent blinded calibration, complete-supplement audit or scientific peer review is claimed by this adversarial pass either.

**Approval:** Following adversarial review and the corrections listed above, the revised document is approved. - Claude Opus 5.5 (Anthropic), 2026-10-14.

## REFERENCES

1. Zhang Y, Gu Y, Ren H et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nature communications. 2020. [PMID 33024120](https://pubmed.ncbi.nlm.nih.gov/33024120/). DOI: 10.1038/s41467-020-18414-8. Access: full_text_partial. Study: PREMOTE_NCT02861261.

2. Ji L, Ma J, Ma Y et al. Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial. JAMA network open. 2025. [PMID 40029660](https://pubmed.ncbi.nlm.nih.gov/40029660/). DOI: 10.1001/jamanetworkopen.2024.62185. Access: full_text_partial. Study: HTD1801_T2D_12week_phaseII.

3. Zhang Y, Li X, Zou D et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. The Journal of clinical endocrinology and metabolism. 2008. [PMID 18397984](https://pubmed.ncbi.nlm.nih.gov/18397984/). DOI: 10.1210/jc.2007-2404. Access: abstract_metadata. Study: Zhang_T2D_dyslipidemia_2008.

4. Panigrahi A, Mohanty S. Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. BMC endocrine disorders. 2023. [PMID 37679692](https://pubmed.ncbi.nlm.nih.gov/37679692/). DOI: 10.1186/s12902-023-01442-y. Access: abstract_metadata. Study: PMID37679692.

5. Harrison SA, Gunn N, Neff GW et al. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nature communications. 2021. [PMID 34535644](https://pubmed.ncbi.nlm.nih.gov/34535644/). DOI: 10.1038/s41467-021-25701-5. Access: abstract_metadata. Study: HTD1801_NCT03656744.

6. Mansour A, Sajjadi-Jazi SM, Gerami H et al. The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial. European journal of nutrition. 2025. [PMID 39998703](https://pubmed.ncbi.nlm.nih.gov/39998703/). DOI: 10.1007/s00394-025-03618-9. Access: abstract_metadata. Study: PMID39998703.

7. Nematollahi S, Pishdad GR, Zakerkish M et al. The effect of berberine and fenugreek seed co-supplementation on inflammatory factor, lipid and glycemic profile in patients with type 2 diabetes mellitus: a double-blind controlled randomized clinical trial. Diabetology & metabolic syndrome. 2022. [PMID 35999562](https://pubmed.ncbi.nlm.nih.gov/35999562/). DOI: 10.1186/s13098-022-00888-9. Access: abstract_metadata. Study: PMID35999562.

8. Shidfar F, Ebrahimi SS, Hosseini S et al. The Effects of Berberis vulgaris Fruit Extract on Serum Lipoproteins, apoB, apoA-I, Homocysteine, Glycemic Control and Total Antioxidant Capacity in Type 2 Diabetic Patients. Iranian journal of pharmaceutical research : IJPR. 2012. [PMID 24250489](https://pubmed.ncbi.nlm.nih.gov/24250489/). DOI: none indexed. Access: abstract_metadata. Study: PMID24250489.

9. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism: clinical and experimental. 2008. [PMID 18442638](https://pubmed.ncbi.nlm.nih.gov/18442638/). DOI: 10.1016/j.metabol.2008.01.013. Access: abstract_metadata. Study: PMID18442638.

10. Nguyen JT, Arian CM, Tanna RS et al. The Pharmacokinetic Interaction Between Metformin and the Natural Product Goldenseal Is Metformin Dose-Dependent: A Three-Arm Crossover Study in Adults With Type 2 Diabetes. Clinical and translational science. 2025. [PMID 39943692](https://pubmed.ncbi.nlm.nih.gov/39943692/). DOI: 10.1111/cts.70120. Access: abstract_metadata. Study: PMID39943692.

11. An Y, Sun Z, Zhang Y et al. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical endocrinology. 2014. [PMID 23869585](https://pubmed.ncbi.nlm.nih.gov/23869585/). DOI: 10.1111/cen.12294. Access: abstract_metadata. Study: PMID23869585.

12. Zhang H, Wei J, Xue R et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism: clinical and experimental. 2010. [PMID 19800084](https://pubmed.ncbi.nlm.nih.gov/19800084/). DOI: 10.1016/j.metabol.2009.07.029. Access: abstract_metadata. Study: PMID19800084.

13. Mai J, Zhang H, Wu M et al. Safety and metabolic effects of HTD1801 in type 2 diabetes and MASLD: a phase Ib randomized trial. Diabetology & metabolic syndrome. 2026. [PMID 42249406](https://pubmed.ncbi.nlm.nih.gov/42249406/). DOI: 10.1186/s13098-026-02202-3. Access: abstract_metadata. Study: HTD1801_28day_phaseIb.

14. Sartore G, Ragazzi E, Antonello G et al. Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial. Nutrients. 2021. [PMID 34371883](https://pubmed.ncbi.nlm.nih.gov/34371883/). DOI: 10.3390/nu13072373. Access: abstract_metadata. Study: PMID34371883.

15. Wei W, Zhao H, Wang A et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European journal of endocrinology. 2012. [PMID 22019891](https://pubmed.ncbi.nlm.nih.gov/22019891/). DOI: 10.1530/EJE-11-0616. Access: abstract_metadata. Study: PMID22019891.

16. Qiu Y, Li M, Zhang Y et al. Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin. Asian journal of psychiatry. 2022. [PMID 34773803](https://pubmed.ncbi.nlm.nih.gov/34773803/). DOI: 10.1016/j.ajp.2021.102896. Access: abstract_metadata. Study: PMID34773803.

17. Dahlberg CJ, Ou JJ, Babish JG et al. A 13-week low glycemic load diet and lifestyle modification program combining low glycemic load protein shakes and targeted nutraceuticals improved weight loss and cardio-metabolic risk factors. Canadian journal of physiology and pharmacology. 2017. [PMID 28800398](https://pubmed.ncbi.nlm.nih.gov/28800398/). DOI: 10.1139/cjpp-2016-0704. Access: abstract_metadata. Study: PMID28800398.

18. Wang X, Zhu HJ, Munoz J et al. An ex vivo approach to botanical-drug interactions: a proof of concept study. Journal of ethnopharmacology. 2015. [PMID 25623616](https://pubmed.ncbi.nlm.nih.gov/25623616/). DOI: 10.1016/j.jep.2015.01.021. Access: abstract_metadata. Study: PMID25623616.

19. Liu X, Li W, Zhang H et al. Biodistribution and pharmacokinetic profile of berberine and its metabolites in hepatocytes. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2022. [PMID 35785560](https://pubmed.ncbi.nlm.nih.gov/35785560/). DOI: 10.1016/j.phymed.2022.154288. Access: abstract_metadata. Study: PMID35785560.

20. Xin HW, Wu XC, Li Q et al. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods and findings in experimental and clinical pharmacology. 2006. [PMID 16541194](https://pubmed.ncbi.nlm.nih.gov/16541194/). DOI: 10.1358/mf.2006.28.1.962774. Access: abstract_metadata. Study: PMID16541194.

21. Alolga RN, Fan Y, Zhang G et al. Pharmacokinetics of a multicomponent herbal preparation in healthy Chinese and African volunteers. Scientific reports. 2015. [PMID 26268432](https://pubmed.ncbi.nlm.nih.gov/26268432/). DOI: 10.1038/srep12961. Access: abstract_metadata. Study: PMID26268432.

22. Guo Y, Chen Y, Tan ZR et al. Repeated administration of berberine inhibits cytochromes P450 in humans. European journal of clinical pharmacology. 2012. [PMID 21870106](https://pubmed.ncbi.nlm.nih.gov/21870106/). DOI: 10.1007/s00228-011-1108-2. Access: abstract_metadata. Study: PMID21870106.

23. Zhang X, Qiu F, Jiang J et al. Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein. Xenobiotica; the fate of foreign compounds in biological systems. 2011. [PMID 21319959](https://pubmed.ncbi.nlm.nih.gov/21319959/). DOI: 10.3109/00498254.2010.529180. Access: abstract_metadata. Study: PMID21319959.

24. Wang Y, Tong Q, Shou JW et al. Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine. Theranostics. 2017. [PMID 28744326](https://pubmed.ncbi.nlm.nih.gov/28744326/). DOI: 10.7150/thno.18290. Access: abstract_metadata. Study: PMID28744326.

25. Kumar P, Liu C, Suliburk J et al. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. The journals of gerontology. Series A, Biological sciences and medical sciences. 2023. [PMID 35975308](https://pubmed.ncbi.nlm.nih.gov/35975308/). DOI: 10.1093/gerona/glac135. Access: abstract_metadata. Study: PMID35975308.

26. Yi L, Maier AB, Tao R et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023. [PMID 36482258](https://pubmed.ncbi.nlm.nih.gov/36482258/). DOI: 10.1007/s11357-022-00705-1. Access: abstract_metadata. Study: PMID36482258.

27. Yoshino M, Yoshino J, Kayser BD et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science (New York, N.Y.). 2021. [PMID 33888596](https://pubmed.ncbi.nlm.nih.gov/33888596/). DOI: 10.1126/science.abe9985. Access: abstract_metadata. Study: PMID33888596.

28. Liao B, Zhao Y, Wang D et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. Journal of the International Society of Sports Nutrition. 2021. [PMID 34238308](https://pubmed.ncbi.nlm.nih.gov/34238308/). DOI: 10.1186/s12970-021-00442-4. Access: abstract_metadata. Study: PMID34238308.

29. Kim M, Seol J, Sato T et al. Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study. Nutrients. 2022. [PMID 35215405](https://pubmed.ncbi.nlm.nih.gov/35215405/). DOI: 10.3390/nu14040755. Access: abstract_metadata. Study: PMID35215405.

30. Morifuji M, Higashi S, Ebihara S et al. Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. GeroScience. 2024. [PMID 38789831](https://pubmed.ncbi.nlm.nih.gov/38789831/). DOI: 10.1007/s11357-024-01204-1. Access: abstract_metadata. Study: PMID38789831.

31. Irie J, Inagaki E, Fujita M et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine journal. 2020. [PMID 31685720](https://pubmed.ncbi.nlm.nih.gov/31685720/). DOI: 10.1507/endocrj.EJ19-0313. Access: abstract_metadata. Study: PMID31685720.

32. Pencina KM, Lavu S, Dos Santos M et al. MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. The journals of gerontology. Series A, Biological sciences and medical sciences. 2023. [PMID 35182418](https://pubmed.ncbi.nlm.nih.gov/35182418/). DOI: 10.1093/gerona/glac049. Access: abstract_metadata. Study: MIB626_14day_PK.

33. Yu M, Alimujiang M, Hu L et al. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver. International journal of biological sciences. 2021. [PMID 33994854](https://pubmed.ncbi.nlm.nih.gov/33994854/). DOI: 10.7150/ijbs.54604. Access: abstract_metadata. Study: PMID33994854.

34. Zhao MM, Lu J, Li S et al. Berberine is an insulin secretagogue targeting the KCNH6 potassium channel. Nature communications. 2021. [PMID 34556670](https://pubmed.ncbi.nlm.nih.gov/34556670/). DOI: 10.1038/s41467-021-25952-2. Access: full_text_partial. Study: KCNH6_models_and_NCT03972215.

35. Dong ZH, Lin HY, Chen FL et al. Berberine improves intralipid-induced insulin resistance in murine. Acta pharmacologica Sinica. 2021. [PMID 32770172](https://pubmed.ncbi.nlm.nih.gov/32770172/). DOI: 10.1038/s41401-020-0493-4. Access: abstract_metadata. Study: PMID32770172.

36. Wang S, Ren H, Zhong H et al. Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study. Gut microbes. 2022. [PMID 34923903](https://pubmed.ncbi.nlm.nih.gov/34923903/). DOI: 10.1080/19490976.2021.2003176. Access: abstract_metadata. Study: PREMOTE_NCT02861261.

37. Zhou F, Bai M, Zhang Y et al. Berberine-induced activation of AMPK increases hepatic FGF21 expression via NUR77. Biochemical and biophysical research communications. 2018. [PMID 29247651](https://pubmed.ncbi.nlm.nih.gov/29247651/). DOI: 10.1016/j.bbrc.2017.12.070. Access: abstract_metadata. Study: PMID29247651.

38. Yue SJ, Liu J, Wang AT et al. Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids. American journal of physiology. Endocrinology and metabolism. 2019. [PMID 30422704](https://pubmed.ncbi.nlm.nih.gov/30422704/). DOI: 10.1152/ajpendo.00256.2018. Access: abstract_metadata. Study: PMID30422704.

39. Yao S, Yuan Y, Zhang H et al. Berberine attenuates the abnormal ectopic lipid deposition in skeletal muscle. Free radical biology & medicine. 2020. [PMID 32745766](https://pubmed.ncbi.nlm.nih.gov/32745766/). DOI: 10.1016/j.freeradbiomed.2020.07.028. Access: abstract_metadata. Study: PMID32745766.

40. Lei L, Wang B, Zhao L et al. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. JAMA network open. 2026. [PMID 41543854](https://pubmed.ncbi.nlm.nih.gov/41543854/). DOI: 10.1001/jamanetworkopen.2025.54152. Access: full_text_partial. Study: PMID41543854.

41. Zhang B, Pan Y, Xu L et al. Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3. Endocrine. 2018. [PMID 30117113](https://pubmed.ncbi.nlm.nih.gov/30117113/). DOI: 10.1007/s12020-018-1689-y. Access: abstract_metadata. Study: PMID30117113.

42. Zhang Z, Zhang H, Li B et al. Berberine activates thermogenesis in white and brown adipose tissue. Nature communications. 2014. [PMID 25423280](https://pubmed.ncbi.nlm.nih.gov/25423280/). DOI: 10.1038/ncomms6493. Access: abstract_metadata. Study: PMID25423280.

43. Li W, Li D, Kuang H et al. Berberine increases glucose uptake and intracellular ROS levels by promoting Sirtuin 3 ubiquitination. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020. [PMID 31706105](https://pubmed.ncbi.nlm.nih.gov/31706105/). DOI: 10.1016/j.biopha.2019.109563. Access: abstract_metadata. Study: PMID31706105.

44. Bai M, Liu Y, Zhou F et al. Berberine inhibits glucose oxidation and insulin secretion in rat islets. Endocrine journal. 2018. [PMID 29467344](https://pubmed.ncbi.nlm.nih.gov/29467344/). DOI: 10.1507/endocrj.EJ17-0543. Access: abstract_metadata. Study: PMID29467344.

45. Yan HM, Xia MF, Wang Y et al. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PloS one. 2015. [PMID 26252777](https://pubmed.ncbi.nlm.nih.gov/26252777/). DOI: 10.1371/journal.pone.0134172. Access: abstract_metadata. Study: NAFLD_NCT00633282.

46. Zhang Q, Xiao X, Feng K et al. Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism. Evidence-based complementary and alternative medicine : eCAM. 2011. [PMID 20953398](https://pubmed.ncbi.nlm.nih.gov/20953398/). DOI: 10.1155/2011/924851. Access: abstract_metadata. Study: PMID20953398.

47. Tian Y, Cai J, Gui W et al. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation. Drug metabolism and disposition: the biological fate of chemicals. 2019. [PMID 30409838](https://pubmed.ncbi.nlm.nih.gov/30409838/). DOI: 10.1124/dmd.118.083691. Access: abstract_metadata. Study: PMID30409838.

48. Yin J, Gao Z, Liu D et al. Berberine improves glucose metabolism through induction of glycolysis. American journal of physiology. Endocrinology and metabolism. 2008. [PMID 17971514](https://pubmed.ncbi.nlm.nih.gov/17971514/). DOI: 10.1152/ajpendo.00211.2007. Access: abstract_metadata. Study: PMID17971514.

49. Feng R, Shou JW, Zhao ZX et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Scientific reports. 2015. [PMID 26174047](https://pubmed.ncbi.nlm.nih.gov/26174047/). DOI: 10.1038/srep12155. Access: abstract_metadata. Study: PMID26174047.

50. Zhou L, Wang X, Shao L et al. Berberine acutely inhibits insulin secretion from beta-cells through 3',5'-cyclic adenosine 5'-monophosphate signaling pathway. Endocrinology. 2008. [PMID 18511510](https://pubmed.ncbi.nlm.nih.gov/18511510/). DOI: 10.1210/en.2007-1752. Access: abstract_metadata. Study: PMID18511510.

51. Jeong HW, Hsu KC, Lee JW et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. American journal of physiology. Endocrinology and metabolism. 2009. [PMID 19208854](https://pubmed.ncbi.nlm.nih.gov/19208854/). DOI: 10.1152/ajpendo.90599.2008. Access: abstract_metadata. Study: PMID19208854.

52. Di Bisceglie AM, Watts GF, Lavin P et al. Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. Lipids in health and disease. 2020. [PMID 33183320](https://pubmed.ncbi.nlm.nih.gov/33183320/). DOI: 10.1186/s12944-020-01406-4. Access: abstract_metadata. Study: HTD1801_NCT03381287.

53. Jiang SJ, Dong H, Li JB et al. Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats. World journal of gastroenterology. 2015. [PMID 26167077](https://pubmed.ncbi.nlm.nih.gov/26167077/). DOI: 10.3748/wjg.v21.i25.7777. Access: abstract_metadata. Study: PMID26167077.

54. Liu LZ, Cheung SC, Lan LL et al. Berberine modulates insulin signaling transduction in insulin-resistant cells. Molecular and cellular endocrinology. 2010. [PMID 20036710](https://pubmed.ncbi.nlm.nih.gov/20036710/). DOI: 10.1016/j.mce.2009.12.027. Access: abstract_metadata. Study: PMID20036710.

55. Richie JP, Nichenametla S, Neidig W et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European journal of nutrition. 2015. [PMID 24791752](https://pubmed.ncbi.nlm.nih.gov/24791752/). DOI: 10.1007/s00394-014-0706-z. Access: abstract_metadata. Study: PMID24791752.

56. Pencina KM, Valderrabano R, Wipper B et al. Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. The Journal of clinical endocrinology and metabolism. 2023. [PMID 36740954](https://pubmed.ncbi.nlm.nih.gov/36740954/). DOI: 10.1210/clinem/dgad027. Access: abstract_metadata. Study: MIB626_28day_physiology.

57. Igarashi M, Nakagawa-Nagahama Y, Miura M et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. npj aging. 2022. [PMID 35927255](https://pubmed.ncbi.nlm.nih.gov/35927255/). DOI: 10.1038/s41514-022-00084-z. Access: abstract_metadata. Study: PMID35927255.

58. Okabe K, Yaku K, Uchida Y et al. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Frontiers in nutrition. 2022. [PMID 35479740](https://pubmed.ncbi.nlm.nih.gov/35479740/). DOI: 10.3389/fnut.2022.868640. Access: abstract_metadata. Study: PMID35479740.

59. Katayoshi T, Uehata S, Nakashima N et al. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Scientific reports. 2023. [PMID 36797393](https://pubmed.ncbi.nlm.nih.gov/36797393/). DOI: 10.1038/s41598-023-29787-3. Access: abstract_metadata. Study: PMID36797393.

60. Fukamizu Y, Uchida Y, Shigekawa A et al. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Scientific reports. 2022. [PMID 36002548](https://pubmed.ncbi.nlm.nih.gov/36002548/). DOI: 10.1038/s41598-022-18272-y. Access: abstract_metadata. Study: PMID36002548.

61. Gu Y, Zhang Y, Shi X et al. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta. 2010. [PMID 20298851](https://pubmed.ncbi.nlm.nih.gov/20298851/). DOI: 10.1016/j.talanta.2010.01.015. Access: abstract_metadata. Study: Zhang_T2D_dyslipidemia_2008.

62. Zhao JV, Sarsani V, Chen B et al. Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization. NPJ cardiovascular health. 2026. [PMID 41882153](https://pubmed.ncbi.nlm.nih.gov/41882153/). DOI: 10.1038/s44325-026-00113-w. Access: abstract_metadata. Study: Berberine_signature_NCT03770325_and_UKBiobank.

63. Nikseresht M, Dabidi Roshan V, Nasiri K. Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes. Physiological reports. 2024. [PMID 39107107](https://pubmed.ncbi.nlm.nih.gov/39107107/). DOI: 10.14814/phy2.16146. Access: abstract_metadata. Study: PMID39107107.

## Source-specific evidence cards

### [1] Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study).

**Shows:** PREMOTE randomized drug-naive newly diagnosed T2D patients to synthesized berberine 1.2g daily or matched placebo for 12 weeks after common gentamicin pretreatment; original Methods verify concealed age-stratified allocation and blinding. HbA1c reduction -0.99 vs -0.59 percentage points; more GI adverse events. Original Results 391/409 primary-analysis participants; probiotic addition did not improve HbA1c.

**Does not show:** Observed treatment effect is conditional on this antibiotic/lifestyle background and duration; microbial covariance does not prove unique human mediation or long-term complication benefit.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph9, 1:Results:paragraph17, 1:Results:paragraph18, 3:Methods:paragraph0, 3:Methods:paragraph1, 3:Methods:paragraph2, 3:Methods:paragraph55, 3:Methods:paragraph56, 3:Methods:paragraph76. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [2] Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial.

**Shows:** Distinct HTD1801 berberine-ursodeoxycholate formulation 113 randomized T2D patients for 12 weeks; original Methods/Results confirm matched placebo and placebo-adjusted HbA1c -0.4/-0.7 percentage points by dose; weight remained stable.

**Does not show:** BUDCA is a new combined molecular entity; benefit cannot be assigned to ordinary berberine alone or borrowed for GLP1 weight-loss equivalence. No cardiovascular event endpoint.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph3, 1:Methods:paragraph4, 2:Results:paragraph0, 2:Results:paragraph5, 2:Results:paragraph18, 2:Results:paragraph20. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [3] Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine.

**Shows:** 116 T2D/dyslipidemia patients randomly allocated berberine 1g daily or placebo for 3 months; HbA1c 7.5 to 6.6 and fasting/postload glucose improvements differed significantly from placebo; constipation in 5.

**Does not show:** Within-arm change is not the treatment difference; clamp disposal change did not differ significantly between arms P=.063. Abstract-level access does not verify every allocation/adherence detail or hard outcomes.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [4] Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial.

**Shows:** 34 prediabetic participants in 12 week double-blind pilot; branded berberine 1.5g daily improved HbA1c and fasting/OGTT markers versus placebo.

**Does not show:** Baseline prediabetes is outside registered T2D scope; small pilot does not establish prevention of diabetes, GLP1 equivalence, or durable clinical outcomes.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [5] A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes.

**Shows:** 100 presumed NASH plus T2D participants randomized 18 weeks to BUDCA versus placebo; high-dose liver fat -4.8 vs -2.0%, glycemic and weight improvements reported.

**Does not show:** UDCA-containing ionic salt differs from pure berberine; liver-fat imaging and secondary glycemia do not establish biopsy resolution or class equivalence.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [6] The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial.

**Shows:** 12 week double-blind T2D trial of berberine 1.2g plus cinnamon 600mg daily versus placebo reported lower fasting glucose and HbA1c but no anthropometric difference.

**Does not show:** No berberine-only or cinnamon-only dismantling arms; bundle effect cannot isolate berberine or validate the glutathione/NMN stack.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

### [7] The effect of berberine and fenugreek seed co-supplementation on inflammatory factor, lipid and glycemic profile in patients with type 2 diabetes mellitus: a double-blind controlled randomized clinical trial.

**Shows:** 50 randomized T2D patients received 900mg berberine plus 600mg fenugreek daily or placebo for 12 weeks; fasting-glucose/insulin between-arm signals and SF12 gains; HbA1c improvement reported within arm.

**Does not show:** Within-arm HbA1c is insufficient evidence of between-arm efficacy; no single-component arms or exact triple stack; small trial and many endpoints.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

### [8] The Effects of Berberis vulgaris Fruit Extract on Serum Lipoproteins, apoB, apoA-I, Homocysteine, Glycemic Control and Total Antioxidant Capacity in Type 2 Diabetic Patients.

**Shows:** 31 T2D participants randomized 3 months to Berberis fruit extract 3g daily or placebo; glucose/insulin and lipid effects positive while HbA1c showed no significant between-arm change.

**Does not show:** Fruit extract is multicomponent and dose not equivalent to isolated berberine; this null HbA1c does not falsify the pure-drug exposure hypothesis.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [9] Efficacy of berberine in patients with type 2 diabetes mellitus.

**Shows:** Study A 36 newly diagnosed T2D adults randomized berberine versus metformin for 3 months with similar glycemic reductions; Study B 48 poorly controlled adults added berberine and HbA1c fell; GI effects 34.5% across reported patients.

**Does not show:** Active-comparator pilot was not a powered noninferiority demonstration; uncontrolled add-on StudyB cannot isolate treatment effect. Metformin similarity is not modern GLP1 equivalence.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [10] The Pharmacokinetic Interaction Between Metformin and the Natural Product Goldenseal Is Metformin Dose-Dependent: A Three-Arm Crossover Study in Adults With Type 2 Diabetes.

**Shows:** T2D three-arm crossover goldenseal/metformin interaction study showed aggregate metformin AUC ratio 0.93 within no-effect band, but dose-dependent reductions around 20% at lower metformin dose; HbA1c exploratory reduction.

**Does not show:** Goldenseal contains multiple alkaloids; brief PK does not establish pure-berberine 12 week efficacy or the absence of clinically important individual interactions.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [11] The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment.

**Shows:** 150 PCOS infertility patients randomized berberine/metformin/placebo beforeIVF; metabolic and pregnancy outcomes improved, with more live births than metformin reported.

**Does not show:** PCOS/IVF population and reproductive endpoints are outside T2D scope; no GLP1 comparator, weight-loss equivalence, or general pregnancy-safety demonstration.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [12] Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.

**Shows:** Human cell lines showed increased insulin-receptor expression and clinical T2D treatment HbA1c/fasting glucose reductions similar to metformin/rosiglitazone; peripheral lymphocyte receptor signal increased.

**Does not show:** Abstract does not report clinical duration or sufficient comparator/control detail for registered threshold credit; lymphocyte marker correlation does not isolate causal receptor mediation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [13] Safety and metabolic effects of HTD1801 in type 2 diabetes and MASLD: a phase Ib randomized trial.

**Shows:** PhaseIb 48 T2D/MASLD patients included treatment-naive cohorts and 12 on stable metformin; 28 day HTD1801 exposure improved fasting/postprandial measures with tolerable short-term events.

**Does not show:** Only 28 days and distinct BUDCA formulation; retrospectively registered. Does not meet 12 week pure-berberine SC2 or demonstrate chronic safety.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [14] Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial.

**Shows:** 12 week randomized add-on formulation berberine/hesperidin/chromium plus metformin improved HbA1c and fasting glucose versus metformin-only control.

**Does not show:** No ingredient dismantling, placebo masking not established in abstract, and composition differs from exact glutathione/NMN stack; relative HbA1c change not percentage-point effect.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

### [15] A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome.

**Shows:** 89 PCOS/IR women randomized berberine/metformin/placebo with common cyproterone for 3 months; metabolic and hormonal effects versus placebo.

**Does not show:** PCOS and common hormonal treatment differ from baseline T2D; metabolic marker effects do not establish GLP1 equivalence or cardiovascular benefit.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [16] Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin.

**Shows:** 65 schizophrenia patients on stable antipsychotic randomized 8 weeks; 49 completed; berberine weight -1.10kg versus placebo+1.45kg, with leptin covariation.

**Does not show:** Attrition and distinct drug-induced weight-gain context; no baseline T2D requirement,12 week observation, GLP1 head-to-head, or proof leptin mediates effect.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [17] A 13-week low glycemic load diet and lifestyle modification program combining low glycemic load protein shakes and targeted nutraceuticals improved weight loss and cardio-metabolic risk factors.

**Shows:** 44 overweight adults randomized open-label diet versus multinutraceutical/protein-shake program 13 weeks; greater risk-factor/weight changes in bundle; 12 discontinued before week 9.

**Does not show:** Diet and many ingredients changed together; authors cannot separate supplement from synergy. Predicted Framingham risk is not observed event reduction and exact triple stack untested.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

### [18] An ex vivo approach to botanical-drug interactions: a proof of concept study.

**Shows:** Post-botanical human plasma incubation predicted CYP inhibition better than artificial buffers and mirrored goldenseal clinical interactions.

**Does not show:** Method-development and multialkaloid exposures do not establish pure-berberine clinical net benefit; ex vivo assay is not a long-term stack safety trial.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [19] Biodistribution and pharmacokinetic profile of berberine and its metabolites in hepatocytes.

**Shows:** HepG2 LCMS identified phaseI/II berberine metabolites and intracellular enrichment of demethyleneberberine.

**Does not show:** Transformed cells and metabolite distribution cannot establish systemic target exposure, mechanism necessity, or clinical T2D glycemic efficacy.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [20] The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers.

**Shows:** Two small healthy-male PK groups found no significant CsA change at 6mg/kg but 19.2% AUC increase at 3mg/kg with berberine.

**Does not show:** Dose-specific interaction signal and proposed CYP/gastric mechanisms not isolated; does not quantify clinical transplant harms or safety of exact stack.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [21] Pharmacokinetics of a multicomponent herbal preparation in healthy Chinese and African volunteers.

**Shows:** Six healthy volunteers took multicomponent K601; berberine and other absorbed alkaloid PK measured, with apparent population differences.

**Does not show:** Tiny multicomponent influenza-preparation exposure study; no T2D outcome, no pure-drug pharmacodynamic mediation, and no population-wide ethnic PK inference.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [22] Repeated administration of berberine inhibits cytochromes P450 in humans.

**Shows:** Randomized crossover repeated 900mg/day berberine 2 weeks in healthy men decreased CYP2D6/2C9/3A4 activity; midazolam AUC about 40% higher.

**Does not show:** Healthy-probe PK and short duration do not establish all-drug interactions or net long-term stack benefit; legitimate interaction evidence narrows simple safety narratives.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [23] Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein.

**Shows:** Caco2 transport experiments with Pgp/MRP inhibitors identify berberine as Pgp substrate and increased absorptive transport with inhibitors.

**Does not show:** Cell transport does not measure clinical bioavailability or disease phenotype; apparent paper-unit formatting retained rather than silently corrected.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [24] Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine.

**Shows:** High-fat-fed hamsters showed higher gut nitroreductase, berberine absorption and lipid response; human hyperlipidemia PK correlated with fecal enzyme activity.

**Does not show:** Human correlation and hamster metabolic response do not establish human T2D microbial necessity; normal-diet lipid null is context specific, not a chronic glycemic boundary.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [25] Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial.

**Shows:** 24 older adults randomized 16 weeks GlyNAC versus alanine, with functional and molecular improvements; young comparison received 2 weeks.

**Does not show:** Glycine/NAC precursors are not direct glutathione and no berberine/NMN combination; small multi-endpoint experiment does not validate exact stack or lifespan extension.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [26] The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.

**Shows:** 80 healthy middle-aged participants randomized 60 days NMN dose groups/placebo; NAD and 6 minute-walk gains, HOMAIR no significant difference; per-protocol analysis.

**Does not show:** Ingredient-specific short-term outcomes and biological-age algorithm do not establish exact-stack benefit, diabetes treatment, or aging reversal.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [27] Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.

**Shows:** 10 week double-blind NMN trial in overweight/obese postmenopausal prediabetic women improved clamp muscle glucose disposal and insulin signaling.

**Does not show:** No T2D berberine arm or triple stack; local muscle insulin sensitivity does not establish systemic clinical glycemic outcomes or mortality benefit.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [28] Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study.

**Shows:** 48 amateur runners randomized NMN dose groups plus common training 6 weeks; ventilatory-threshold measures improved, VO2max and peak power did not.

**Does not show:** Small sports cohort and selective physiological outcomes; no exact stack, disease outcomes, or general aging benefit.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [29] Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study.

**Shows:** 108 older adults randomized timing-specific NMN/placebo 12 weeks; sit-to-stand improved in allgroups and afternoon drowsiness improved with NMN and placebo; interactions reported.

**Does not show:** Largest within-arm effect does not show universal NMN superiority; multiple groups/endpoints and no exact stack or glycemic disease scope.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [30] Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study.

**Shows:** 60 older adults randomized NMN250mg/placebo 12 weeks; primary stepping test null, secondary walking-time/NAD/sleep signals positive.

**Does not show:** Primary null must accompany secondary positives; ingredient trial cannot establish triple-stack net benefit or extended healthy life expectancy.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [31] Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men.

**Shows:** Ten healthy men single-arm acute oralNMN100/250/500mg with metabolites and 5 hour laboratory measures; no major immediate abnormalities.

**Does not show:** No randomized comparator or repeated exposure; absence of acute symptoms does not establish long-term safety, clinical efficacy, or stack benefit.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [32] MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults.

**Shows:** 32 older overweight/obese adults randomized pharmaceutical NMN14 days; substantial dose-related NAD rise with short-term tolerability.

**Does not show:** Biochemical exposure foundation only; no exact stack, durability, or functional disease benefit and no aging-causation proof.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [33] Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver.

**Shows:** Mouse berberine improved adiposity/IR while inhibiting gut/liver complexI; fecal transplantation failed to transfer metabolic effect, favoring nonmicrobial explanation in this model.

**Does not show:** Mouse doses and tissue metabolism do not establish chronic human mediation; transplant negative contradicts obligatory transferable microbiome model, not all microbiome roles.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [34] Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.

**Shows:** Original M/R verify global and beta-cell Kcnh6 knockout abolished acute berberine glucose/insulin effect while tolbutamide remained active; 15 healthy men single-dose crossover clamp showed second-phase secretion increase.

**Does not show:** Animal 560mg/kg acute drug dependence plus healthy clamp does not establish endogenous human 12 week T2D mediation or GLP1 equivalence. Attached 34716337 corrects an author-name typo only.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph4, 1:Results:paragraph6, 1:Results:paragraph26, 3:Methods:paragraph1, 3:Methods:paragraph7, 3:Methods:paragraph17, 3:Methods:paragraph18, 3:Methods:paragraph21. No complete-paper or supplement audit claimed. ErratumIn: PMID34716337. Subclaims: SC1, SC2.

### [35] Berberine improves intralipid-induced insulin resistance in murine.

**Shows:** Acute intralipid insulin resistance improved with berberine; CypD deletion attenuated disease and diminished additional treatment effect; muscle-specific evidence with cells.

**Does not show:** Acute clamp model and knockout baseline alteration do not isolate all chronic T2D treatment mechanisms or human relevance.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [36] Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study.

**Shows:** 365 PREMOTE participants secondary meal-test lipid analysis; probiotic plus berberine improved postprandial lipids, with Bbreve/fadD laboratory support.

**Does not show:** Same parent trial 33024120 and different endpoint; not independent glycemic replication, and postprandial lipid synergy is not HbA1c synergy or clinical event reduction.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [37] Berberine-induced activation of AMPK increases hepatic FGF21 expression via NUR77.

**Shows:** Primary mouse hepatocytes showed AMPK/NUR77/FGF21 response; constitutively activeAMPK and compoundC supported pathway involvement.

**Does not show:** Expression endpoint in isolated cells plus ectopic activation/inhibitor specificity cannot establish endogenous organismal or clinical phenotype dependency.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [38] Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids.

**Shows:** High-fat-fed mouse metabolic benefit cooccurred with lower BCAAs and microbiome shifts; ex vivo catabolism and human BCAA/glycemia data included.

**Does not show:** Covarying pathways and unspecified human treatment design do not show unique microbial/BCAA mediation or satisfy registered clinical trial duration/comparator.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [39] Berberine attenuates the abnormal ectopic lipid deposition in skeletal muscle.

**Shows:** Mouse/myocyte berberine reduced ectopic muscle lipid and altered mitochondrial function; AMPK/PGC1alpha RNAinterference/adenovirus supported pathway linkage.

**Does not show:** Lipid/mitochondrial endpoints and experimental constructs do not prove human T2D treatment mechanism or longevity benefits.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [40] Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.

**Shows:** Original Methods/Results: 337 diabetes-free obese MASLD participants randomized 6 months 1g/day berberine or matching placebo after tolerance/adherence run-in; VAT, liver fat, body composition and HbA1c effects null despite modest LDL/apoB/CRP reduction.

**Does not show:** Excludes diabetes and selects tolerant adherers; does not refute T2D glycemic efficacy or establish all-comer safety. Strong boundary against broad adiposity and biomarker-to-weight extrapolation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph8, 2:Results:paragraph0, 2:Results:paragraph7, 2:Results:paragraph13. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [41] Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3.

**Shows:** Sirt3 knockout/overexpression and metabolic assays supported berberine-related mitochondrial/AMP/cAMP/glucose mechanisms and glucagon-pathway inhibition.

**Does not show:** Multiple downstream routes and model intervention do not isolate human chronic mediation; mitochondrial inhibition is not automatically clinical mitochondrial injury.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [42] Berberine activates thermogenesis in white and brown adipose tissue.

**Shows:** Obese db/db mice berberine increased energy expenditure/BAT and limited weightgain; hypothalamicAMPK genetic activation did not prevent effect.

**Does not show:** Obesity model thermogenesis does not establish adult clinical weightloss equivalence to GLP1 medicines or necessity of every proposedAMPK site.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [43] Berberine increases glucose uptake and intracellular ROS levels by promoting Sirtuin 3 ubiquitination.

**Shows:** Ovarian KGN cells showed glucose uptake together with SIRT3 ubiquitination, mitochondrial depolarization/complexI inhibition and dose-related ROS/apoptosis signals.

**Does not show:** Transformed ovarian-cell concentrations cannot demonstrate human T2D efficacy or systemic toxicity; beneficial glucose uptake and adverse cell effects need exposure translation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [44] Berberine inhibits glucose oxidation and insulin secretion in rat islets.

**Shows:** Rat islets berberine inhibited glucose-stimulated secretion/OCR; inhibition disappeared at 25mM glucose and compoundC did not reverse OCR effect.

**Does not show:** Context-dependent secretion conflicts with an unconditional secretagogue narrative; isolated islet result not clinical efficacy falsification or chronic human toxicity.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [45] Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.

**Shows:** 184 NAFLD patients randomized open-label lifestyle/pluspioglitazone/plus berberine 16 weeks; liverfat and weight/IR improved, measured berberine exposure and animal liver studies.

**Does not show:** Different NAFLD eligibility, common lifestyle and openlabel design; not all participants established T2D or GLP1 comparators; no unique human hepatic mechanism.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [46] Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism.

**Shows:** KKAy mice randomized berberine 250mg/kg/day or control; glucose/IR/lipids improved with altered skeletal-muscle transcript profile.

**Does not show:** Transcript changes nominate multiple mechanisms without necessity/rescue; single-species treatment does not qualify chronic human mechanism inference.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [47] Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation.

**Shows:** Five-day mouse/in vitro bacterial exposure altered Clostridia/BSH/bile acids and intestinalFXR-associated signals.

**Does not show:** Short microbial/metabolite perturbation without matched human glycemic dependency; not proven single mediator of clinical benefit.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [48] Berberine improves glucose metabolism through induction of glycolysis.

**Shows:** Five-week obese-rat treatment improved IR; multiple cell lines increased glycolysis/AMPATP while oxygen consumption declined andAMPK rose.

**Does not show:** Energy-stress response and cell glucose consumption do not establish human endocrine mechanism; no direct chronicT2D complication endpoint.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [49] Transforming berberine into its intestine-absorbable form by the gut microbiota.

**Shows:** Gut bacteria reduced berberine into more absorbable dihydroberberine; antibiotics lowered conversion/exposure and lipid/glucose effects in KKAy mice.

**Does not show:** Broad antibiotics alter many processes; absorbed metabolite mechanism and animal doses cannot alone prove human microbiome-specific causal mediation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [50] Berberine acutely inhibits insulin secretion from beta-cells through 3',5'-cyclic adenosine 5'-monophosphate signaling pathway.

**Shows:** Six-week high-fat-rat treatment improved glucose while lowering insulin; acuteislet/MIN6 berberine inhibited secretion,24hourpretreatment improved response and attenuated glucolipotoxicity.

**Does not show:** Time/glucose-dependent secretion reversals preclude a universal single-direction secretagogue narrative; culture effects not chronic clinical harm.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [51] Berberine suppresses proinflammatory responses through AMPK activation in macrophages.

**Shows:** Obese-mouse adipose and isolatedmacrophage inflammation decreased; compoundC/dominant-negativeAMPK abolished cellular anti-inflammatory effects.

**Does not show:** Cell-specific inhibition and inflammatory markers do not establish clinical T2D mediation, mortality benefit, or exact-stack safety.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [52] Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia.

**Shows:** 50 hyperlipidemia patients randomized 28 days dose-ranging BUDCA/placebo; highdose LDL lowered10.4%, with shorttermPK/tolerability foundation.

**Does not show:** Not baselineT2D, ordinary berberine,12 weeks, or event reduction; no GLP1 equivalence.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [53] Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.

**Shows:** 40rats randomized normal/diabetic/drug groups; 12 week berberine improved glucose/IR and LKB1AMPKTORC2 markers versus diabetic model.

**Does not show:** No pathway-specific genetic rescue and disease induction/doses differ from humanT2D; protein covariance not necessary mediator.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [54] Berberine modulates insulin signaling transduction in insulin-resistant cells.

**Shows:** Insulin-resistant ratmuscle cells showed enhancedGLUT4/glucose uptake and IRS1/PKC/mTOR-related signaling withberberine.

**Does not show:** Cellculture metabolic rescue does not establish human chronic clinical causality; multiple route changes not necessity of a single pathway.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [55] Randomized controlled trial of oral glutathione supplementation on body stores of glutathione.

**Shows:** 54healthy adults randomized 6 months oralglutathione/placebo; GSHstores increased, washedout, immune-marker subset signal.

**Does not show:** Target engagement and antioxidant ratios are not functionalnetbenefit of berberine/GSH/NMN stack or diabetes treatment.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [56] Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study.

**Shows:** 30 overweight older adults randomized 28 days NMN/placebo; NAD,weight,lipid/diastolic signals improved but insulin sensitivity,physicalperformance and hepatic/intraabdominalfat null.

**Does not show:** Short small ingredienttrial with many endpoints; no exactstack or durable outcome, and NAD rise not equivalent functional rejuvenation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [57] Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men.

**Shows:** Olderhealthy men randomized 6/12weekNMN; NAD rise and nominal gait/leftgrip gains, bodycomposition null.

**Does not show:** Nominal selective outcomes need replication; no exactstack, T2D clinical endpoint, or agingtrajectory inference.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [58] Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects.

**Shows:** Thirty healthy adults randomizedNMN250mg/placebo 12 weeks; NAD/NAMN increased, routine physiological/laboratory measures showed no major adverse signal.

**Does not show:** Bloodtarget engagement and short safety do not establish functional benefit, lifelong safety, or triple-stack efficacy.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [59] Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial.

**Shows:** 36healthy middle-aged adults randomized 12weekNMN; serum nicotinamide increased but pulsewavevelocity difference nonsignificant.

**Does not show:** Trend cannot substitute for between-arm arterialfunction benefit; no exactstack or disease events.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [60] Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women.

**Shows:** 31healthy adults randomized 1250mg/dayNMN/placebo 4 weeks; no severe adverseevents or out-of-range physiologic changes.

**Does not show:** Small short-term safety study cannot establish chronic safety or exact-stack netbenefit.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [61] Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics.

**Shows:** 60T2D/dyslipidemia samples berberine/placebo metabolomics showed reductions in freefattyacids and treatment-separated profiles.

**Does not show:** Likely related to 2008Zhang diabetes cohort; conservatively grouped until provenindependent. Metabolic covariance not causalmediator or new HbA1c clinicaltrial.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [62] Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization.

**Shows:** 2026original built berberine-response proteomic/hormone signature from RCT and linked it to IHD/diabetes via UKBiobank and MR; signalOR.85IHD/.88diabetes.

**Does not show:** Genetic instrument is a derived signature rather than assigned oralberberine exposure; does not demonstrate clinicalevent treatmentbenefit or GLP1 noninferiority. Cohort/MRcomponents not counted as multiple independentT2D drugtrials.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [63] Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes.

**Shows:** 54 overweight prediabetic men randomized 6 groups 8 weeks HIIT/berberine combinations; exercise benefited glucose/IR, adding berberine did not add benefit; berberine-only within-arm changes.

**Does not show:** Prediabetes label with unusually broad 110–180mg/dL FBG reported and 8 weeks outside registered eligibility; within-arm change not treatment contrast. No GLP1 head-to-head.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.